Comparing Silexion Therapeutics (NASDAQ:SLXN) and Tourmaline Bio (NASDAQ:TRML)

Tourmaline Bio (NASDAQ:TRML) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, institutional ownership and valuation.

Profitability

This table compares Tourmaline Bio and Silexion Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tourmaline Bio	N/A	-20.97%	-20.56%
Silexion Therapeutics	N/A	N/A	-249.43%

Earnings and Valuation

This table compares Tourmaline Bio and Silexion Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tourmaline Bio	N/A	N/A	-$42.12 million	($3.21)	-5.16
Silexion Therapeutics	N/A	N/A	$260,000.00	N/A	N/A

Insider & Institutional Ownership

91.9% of Tourmaline Bio shares are owned by institutional investors. Comparatively, 10.9% of Silexion Therapeutics shares are owned by institutional investors. 11.0% of Tourmaline Bio shares are owned by insiders. Comparatively, 33.0% of Silexion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Tourmaline Bio has a beta of 2.11, meaning that its share price is 111% more volatile than the S&P 500. Comparatively, Silexion Therapeutics has a beta of 0.06, meaning that its share price is 94% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Tourmaline Bio and Silexion Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tourmaline Bio	0	0	7	0	3.00
Silexion Therapeutics	0	0	1	0	3.00

Tourmaline Bio currently has a consensus target price of $49.33, suggesting a potential upside of 197.91%. Silexion Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 445.85%. Given Silexion Therapeutics’ higher possible upside, analysts clearly believe Silexion Therapeutics is more favorable than Tourmaline Bio.

About Tourmaline Bio

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.